National Medical Insurance Bureau Deputy Director Li Tao met with the Government of Singapore Investment Corporation

On July 31st, according to the National Medical Insurance Administration, on July 28th, Li Tao, deputy director of the National Medical Insurance Administration, met with the Government Investment Corporation of Singapore (GIC) in Beijing, and the two sides had in-depth exchanges on medical insurance support for the development of innovative drugs. Li Tao said that in the next step, the National Medical Insurance Administration will continue to implement relevant policies and measures, and increase openness to help the development of medical institutions, medical technology progress, drug innovation and improvement, and industrial transformation and upgrading. Welcome domestic and foreign investment institutions to pay attention to China's innovative drugs, invest in China's innovative drugs, pay attention to health, and invest in health. The Government of Singapore Investment Corporation said that the international competitiveness of China's innovative drug enterprises is increasing day by day, and the policy signals of government departments such as the National Medical Insurance Administration of China to support the high-quality development of innovative drugs are clear and clear. The market has good expectations for the development of China's innovative drug industry. It is hoped that the communication with China's National Medical Insurance Administration and other departments will continue to be strengthened in the future.